Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet.
Avner FinkEric HungIndranil SinghYinon Ben-NeriahPublished in: European journal of immunology (2021)
Acute myeloid leukemia (AML) is a highly aggressive disease with high relapse and mortality rates. Recent years have shown a surge in novel therapeutic development for AML, both in clinical and preclinical stages. These developments include targeted therapies based on AML-specific molecular signatures as well as more general immune modulation and vaccination studies. In this review, we will explore the evolving arena of AML therapy and suggest some intriguing connections between immune system modulation and targeted therapy. Improved understanding of the immune system involvement in various stages of the disease and the crosstalk between immune effectors, targeted therapy, and AML cells can provide a better framework for designing the next generation of AML therapies.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- immune response
- induced apoptosis
- gene expression
- acute lymphoblastic leukemia
- cardiovascular disease
- dna methylation
- cell therapy
- stem cells
- type diabetes
- cell cycle arrest
- mesenchymal stem cells
- coronary artery disease
- risk factors
- endoplasmic reticulum stress
- free survival
- pi k akt